Comparison of serum and plasma MMP-9 level in breast cancer patients and its correlation with the clinical features of the patients

Document Type : Original Article (s)

Authors

1 Assistant Professor, Biology Department, School of Sciences, Isfahan University, Isfahan, Iran.

2 Assistant Professor, Oncology and Radiotherapy Department, Medicine School, Isfahan University of medical sciences, Isfahan, Iran.

3 BS of molecular genetic, Biology Deppartment, School of Sciences, Isfahan University, Isfahan, Iran.

Abstract

Background: Matrix metalloproteinase-9 (MMP-9) has been reported as a new marker gene for several cancers. With respect to the significance function of this gene in diagnosis of cancers in the present study we compare the correlation betweenthe plasma and serum MMP-9 levels and clinical features of breast cancer patients.Methods: In this case-control study, 120breast cancer patients and 87 healthy controls were studded.MMP-9 level was quantitatively measured byzymography and specific kit. The results were compared with clinical features of patients.Finding: Plasma MMP-9 level wassignificantly elevated in breast cancer patients comparedwith the control subjects (P < 0.001). Also there was a correlation between the plasma MMP-9 level and lymph node metastasis (OR, 3.43; P = 0.019) and venous invasion (OR, 4.14; P = 0.033) of the patients. There was no correlation between the serum MMP-9 level and lymphatic metastasis or venous invasion.Conclusion: according to our findings the plasma MMP-9 level  in comparison with the serum MMP-9 level is a better determinant for early diagnosis, lymph node metastasis and venous invasion in patients with breast cancer. 

Keywords

References

  1. Nagase H, Woessner JF, Jr. Matrix metallopro-teinases. J Biol Chem 1999 Jul 30; 274(31): 21491-4.
  2. Ala-aho R, Kahari VM. Collagenases in cancer. Biochimie 2005 Mar;87(3-4):273-86.
  3. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000 Dec;10(6):415-33.
  4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002 Mar;2(3):161-74.
  5. Kahari VM, Saarialho-Kere U. Matrix metallo-proteinases and their inhibitors in tumour growth and invasion. Ann Med 1999 Feb;31(1):34-45.
  6. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al. Mea-surement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999 Jun 30; 878: 212-27.
  7. Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993 Jan 1; 53(1):140-6.
  8. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Cancer Lett 2006 May 8;236(1):125-32.
  9. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005 Sep 1;116(3):422-7.
  10. Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 2000 Mar;20(2B):1307-10.
  11. Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996 Nov;24(5):1058-62.
  12. Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, et al. Elevated levels of serum and plasma metalloproteinases in pa-tients with gastric cancer. Anticancer Res 1997 May;17(3C):2253-8.
  13. Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 1997 Jan;84(1):133-6.
  14. Decock J, Hendrickx W, Wildiers H, Chris-tiaens MR, Neven P, Drijkoningen M, et al. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin Exp Metastasis 2005; 22(6): 495-502.
  15. Kirman I, Jain S, Cekic V, Belizon A, Balik E, Sylla P, et al. Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc 2006 Mar;20(3):482-6.
  16. Jung K. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? J Neuroimmunol 2005 May;162(1-2):1-2.
  17. Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003 Nov;49(11):1956-7.
  18. Mannello F. Effects of blood collection me-thods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003 Feb;49(2):339-40.
  19. Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D, et al. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998 May;44(5):1060-2.
  20. Dragutinovic VV, Radovanovic NS, Izrael-Zivkovic LT, Vrvic MM. Detection of gelatinase B activity in serum of gastric cancer patients. World J Gastroenterol 2006 Jan 7;12(1):105-9.
  21. Rauvala M, Puistola U, Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 2005 Dec;99(3):656-63.
  22. Chen W, Abnet CC, Wei WQ, Roth MJ, Lu N, Taylor PR, et al. Serum markers as predictors of esophageal squamous dysplasia and early cancer. Anticancer Res 2004 Sep;24(5B):3245-9.
  23. Motovali-bashi M, Hojati Z, Sadeghi M. Association between a Single Base Substitution at AP-1 Regulation REgion in MMP-9 gene and Tumor Creation in Breast Tissue. J.Rafsanjan University of Medical Sciences 9[1], 27-36. 2010.
  24. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990 Feb 20;127(1):103-8.
  25. Fujisawa T, Kato Y, Terada A, Iguchi K, Ka-miya H. Matrix metalloproteinase-9 in peripheral blood eosinophils. Int Arch Allergy Immunol 1999; 120 Suppl 1:65-9.
  26. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative se-rum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of ma-trix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000 Mar;20(2B):1085-91.
  27. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001 Jan;95(1):1-4.
  28. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005 Apr;354(1-2):91-9.
  29. Tamura M, Oda M, Matsumoto I, Tsunezuka Y, Kawakami K, Ohta Y, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004 Oct;11(10):928-33.
  30. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier JE, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003 Sep 20;106(5):745-51.
  31. La RG, Pucci-Minafra I, Marrazzo A, Taormi-na P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004 Apr 5;90(7):1414-21.
  32. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 2006 Feb 20;233(1):98-107.
  33. Mannello F, Tonti GA. Gelatinase concentra-tions and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007 Jul 1; 121(1): 216-8.
Journal of Isfahan Medical School
Volume 28, Issue 118 - Serial Number 118
November and December 2011
Pages 1253-1260

Files

History

  • Receive Date: 19 March 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics